Pancreatic Cancer Pain
Conditions
Interventions
experimental group:HD-tACS was delivered by a 4-channel noninvasive noninvasive neurostimulator (NeuStim, China), delivering alternating current (AC) through five circular Ag/AgC1 gel electrodes (3.14
the specific location of each electrode was determined by the International 10/20 EEG System, and the target brain region was the ACC. The stimulation protocol lasted approximately 20 min: the stimula
control subjects:All electrodes were placed in the same position and the same current intensity was delivered only during the first 10 seconds and the last 10 seconds of the 20-minute period to match
Sponsors
Naval Medical Center of PLA
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Be at least 18 years of age. Diagnosed with pancreatic cancer Mild to severe pain symptoms within the past month according to the Numerical Rating Scale (NRS) or Visual Analog Scale (VAS). Patient is able to understand the study procedures and is able to provide written informed consent. The patient agrees to follow the study requirements for the duration of the study, including completion of all scheduled assessments and interventions. Patient does not have a serious cardiac condition such as a pacemaker or other implantable electronic medical device. Patient does not have an allergy to Ag/AgCl gels or electrode materials. Patient is not pregnant or breastfeeding. Patient does not have severe cognitive impairment and is able to self-report pain. Patient is not participating in other clinical trials that may affect pain perception.
Exclusion criteria
Exclusion criteria: Have a serious concomitant medical condition, such as uncontrolled heart disease, serious kidney disease, or serious liver disease, that may affect study results. Presence of neurological disorders such as epilepsy, severe cognitive impairment, or psychiatric disorders may affect study participation. Have bleeding tendencies or coagulation disorders that may increase the risk of HD-tACS treatment. Have a history of increased intracranial pressure, intracranial tumors, or other intracranial disorders. Have an implanted electronic medical device such as a pacemaker or deep brain stimulator. Allergy to any materials used in HD-tACS therapy. Has not obtained informed consent from the patient or his/her legal representative. Patient is considered by the investigator to be unsuitable for participation in this study based on other medical or personal reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| visual analogue scale, VAS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pittsburgh sleep quality index,PSQI;HamiltonAnxiety Scale,HAMA;HamiltonDepression Scale,HAMD;Medical Outcomes Study 36- Item Short Form Health Survey, SF-36;Morphine Quantification Scale, III; | — |
Countries
China
Contacts
Public ContactHaiyan Yue
Naval Medical Center of PLA
Outcome results
None listed